Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone vs. Eplerenone in Duchenne Muscular Dystrophy
NCT02354352Phase 3Completed
- Sponsor
- The Ohio State University
- Start
- Mar 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in Duchenne muscular dystrophy (DMD), sponsored by The Ohio State University. Started Mar 2015; status: completed.
02
Drugs
spironolactone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02354352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354352.